<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>SBIR Phase I:  Construction of Vascular Structures with Human Tropoelastin</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>01/01/2010</AwardEffectiveDate>
<AwardExpirationDate>12/31/2010</AwardExpirationDate>
<AwardTotalIntnAmount>0.00</AwardTotalIntnAmount>
<AwardAmount>199213</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Gregory T. Baxter</SignBlockName>
<PO_EMAI/>
<PO_PHON/>
</ProgramOfficer>
<AbstractNarration>This Small Business Innovation Research (SBIR) Phase I project proposes to make new blood vessels by using a synthesized human protein as a guide for growing human cells into tissues. The guide will be molded into a tubular shape. The protein, a water soluble form of human elastin can be produced by fermentation and will be purified, mixed with a catalyst and cast into tubular shaped molds made of glass or plastic. After the protein has set up in the tubular mold, it will be removed, tested for its strength and ability to stretch, and mixed with human epithelial cells in tissue culture media. The cells will be allowed to grow on and within the solidified protein to form a combination of a strong, elastic vessel surrounded by layers of human cells.&lt;br/&gt;&lt;br/&gt;The broader impacts of this research are the availability of new and better performing blood vessel material for dialysis patients. Dialysis patients experience problems with damage to their blood vessels during the dialysis procedure. These complications currently cost a total of $1.5 billion extra. Reducing the costs, pain and complications by using a new vascular material represents a large benefit to patients and physicians.&lt;br/&gt;&lt;br/&gt;</AbstractNarration>
<MinAmdLetterDate>10/30/2009</MinAmdLetterDate>
<MaxAmdLetterDate>06/08/2010</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>0</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>0945065</AwardID>
<Investigator>
<FirstName>Burt</FirstName>
<LastName>Ensley</LastName>
<PI_MID_INIT/>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Burt Ensley</PI_FULL_NAME>
<EmailAddress>burt@burtensley.com</EmailAddress>
<PI_PHON>9282034127</PI_PHON>
<NSF_ID>000523113</NSF_ID>
<StartDate>10/30/2009</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Protein Genomics</Name>
<CityName>Sedona</CityName>
<ZipCode>863365240</ZipCode>
<PhoneNumber>9282034127</PhoneNumber>
<StreetAddress>PMB 13419</StreetAddress>
<StreetAddress2><![CDATA[2675 W HWY 89A]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Arizona</StateName>
<StateCode>AZ</StateCode>
<CONGRESSDISTRICT>01</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>AZ01</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>828302104</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>PROTEIN GENOMICS INC.</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[University of Arizona]]></Name>
<CityName>Tucson</CityName>
<StateCode>AZ</StateCode>
<ZipCode>857194824</ZipCode>
<StreetAddress><![CDATA[888 N Euclid Ave]]></StreetAddress>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Arizona</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>03</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>AZ03</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<FoaInformation>
<Code>0308000</Code>
<Name>Industrial Technology</Name>
</FoaInformation>
<ProgramElement>
<Code>5371</Code>
<Text>SBIR Phase I</Text>
</ProgramElement>
<ProgramReference>
<Code>1167</Code>
<Text>MULTIDISCIPLINARY BIOTECHNOLOGY</Text>
</ProgramReference>
<ProgramReference>
<Code>1773</Code>
<Text>POLYMERS</Text>
</ProgramReference>
<ProgramReference>
<Code>5371</Code>
<Text>SMALL BUSINESS PHASE I</Text>
</ProgramReference>
<ProgramReference>
<Code>9181</Code>
<Text>BIOPROCESSING/BIOMOLECULAR MATERIALS</Text>
</ProgramReference>
<ProgramReference>
<Code>9183</Code>
<Text>GENERAL FOUNDATIONS OF BIOTECHNOLOGY</Text>
</ProgramReference>
<ProgramReference>
<Code>BIOT</Code>
<Text>BIOTECHNOLOGY</Text>
</ProgramReference>
<Appropriation>
<Code>0110</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2010~199213</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p><strong>This Project Outcomes Report for the General Public</strong> is displayed verbatim as submitted by the Principal Investigator (PI) for this award. &nbsp;Any opinions, findings, and conclusions or recommendations expressed in this Report are those of the PI and do not necessarily reflect the views of the National Science Foundation; NSF has not approved or endorsed its content.</p> <p><strong>This Small Business Innovation Research (SBIR) Phase I project</strong> began to explore the construction of new blood vessels using recombinant human proteins as prototype biomaterials. The results from the Phase I efforts resulted in our ability to form sheet and tubular scaffolds of pure recombinant human tropoelastin. These scaffolds supported robust growth of human cells and displayed biomechanical properties similar to natural arteries from pigs.&nbsp; Furthermore, human tropoelastin was successfully blended with other synthetic and natural (collagen) polymers to form blended polymer sheets.&nbsp; The combination of human collagen and human elastin, the same components that are found in native arteries and veins, has never been tested before in any application.</p> <p><strong>The broader impacts of this research include</strong> access to an entirely new class of biomaterials and most importantly a novel clinical use for a tissue-engineered vascular graft in hemodialysis patients. The total annual cost of vascular access complications in dialysis is estimated to be nearly $8,000 per patient, with a total cost of $1.5 billion, or approximately 10% of the total end-stage renal disease (ESRD) budget.&nbsp; A significant reduction in patient pain and suffering is an additional benefit. We were also successful in recruiting underrepresented students for to work on the proposed research. &nbsp;Advanced educational opportunities and exposure (e.g., Scientific Conference attendance and presentations) were made available to these students.&nbsp;</p> <h1><strong>Publications and Products:</strong></h1> <p><strong>&nbsp;Book Chapter:</strong></p> <p>&nbsp;RS Kellar, J Lancaster, S Goldman, TN McAllister, and N L&rsquo;Heureux.<sup> </sup><strong>&nbsp;<em>&ldquo;Comprehensive Biomaterials &ndash; Cardiovascular Tissue Engineering&rdquo;</em>.&nbsp;&nbsp; </strong>Elsevier Publishing.&nbsp; <em>In Press</em>.&nbsp; 2011.</p> <p><strong>&nbsp;Scientific Abstracts:</strong></p> <p>&nbsp;RS Kellar, R Audet, JP Vande Geest, J Carbary, B Ensley.&nbsp; <strong><em>Recombinant Tropoelastin as a Novel Biomaterial</em></strong>.&nbsp; Surfaces in Biomaterials Foundation Annual Meeting.&nbsp; Atlanta, Georgia.&nbsp; October 18-20, 2010.</p> <p>&nbsp;M Karpinsky, R Audet, JP Vande Geest, J Carbary, B Ensley, R Kellar.&nbsp; <strong><em>Biocompatibility Evaluations and Mechanical testing of an Electro-spun Human Tropoelastin Biomaterial</em></strong>.&nbsp; Surfaces in Biomaterials Foundation Annual Meeting.&nbsp; Atlanta, Georgia.&nbsp; October 18-20, 2010.</p> <p>&nbsp;R Diller, T Johnson, S Potts, E Pinney, R Kellar.&nbsp; <strong><em>Digital Histopathology and Feature Analysis on Consecutive Tissue Sections (FACTS) to Determine Biocompatiblity of Biomedical Implants.</em></strong>&nbsp; Surfaces in Biomaterials Foundation Annual Meeting.&nbsp; Atlanta, Georgia.&nbsp; October 18-20, 2010.</p><br> <p>            Last Modified: 01/16/2011<br>      Modified by: Burt&nbsp;Ensley</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ This Project Outcomes Report for the General Public is displayed verbatim as submitted by the Principal Investigator (PI) for this award.  Any opinions, findings, and conclusions or recommendations expressed in this Report are those of the PI and do not necessarily reflect the views of the National Science Foundation; NSF has not approved or endorsed its content.  This Small Business Innovation Research (SBIR) Phase I project began to explore the construction of new blood vessels using recombinant human proteins as prototype biomaterials. The results from the Phase I efforts resulted in our ability to form sheet and tubular scaffolds of pure recombinant human tropoelastin. These scaffolds supported robust growth of human cells and displayed biomechanical properties similar to natural arteries from pigs.  Furthermore, human tropoelastin was successfully blended with other synthetic and natural (collagen) polymers to form blended polymer sheets.  The combination of human collagen and human elastin, the same components that are found in native arteries and veins, has never been tested before in any application.  The broader impacts of this research include access to an entirely new class of biomaterials and most importantly a novel clinical use for a tissue-engineered vascular graft in hemodialysis patients. The total annual cost of vascular access complications in dialysis is estimated to be nearly $8,000 per patient, with a total cost of $1.5 billion, or approximately 10% of the total end-stage renal disease (ESRD) budget.  A significant reduction in patient pain and suffering is an additional benefit. We were also successful in recruiting underrepresented students for to work on the proposed research.  Advanced educational opportunities and exposure (e.g., Scientific Conference attendance and presentations) were made available to these students.  Publications and Products:   Book Chapter:   RS Kellar, J Lancaster, S Goldman, TN McAllister, and N LÃ†Heureux.  "Comprehensive Biomaterials &ndash; Cardiovascular Tissue Engineering".   Elsevier Publishing.  In Press.  2011.   Scientific Abstracts:   RS Kellar, R Audet, JP Vande Geest, J Carbary, B Ensley.  Recombinant Tropoelastin as a Novel Biomaterial.  Surfaces in Biomaterials Foundation Annual Meeting.  Atlanta, Georgia.  October 18-20, 2010.   M Karpinsky, R Audet, JP Vande Geest, J Carbary, B Ensley, R Kellar.  Biocompatibility Evaluations and Mechanical testing of an Electro-spun Human Tropoelastin Biomaterial.  Surfaces in Biomaterials Foundation Annual Meeting.  Atlanta, Georgia.  October 18-20, 2010.   R Diller, T Johnson, S Potts, E Pinney, R Kellar.  Digital Histopathology and Feature Analysis on Consecutive Tissue Sections (FACTS) to Determine Biocompatiblity of Biomedical Implants.  Surfaces in Biomaterials Foundation Annual Meeting.  Atlanta, Georgia.  October 18-20, 2010.       Last Modified: 01/16/2011       Submitted by: Burt Ensley]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
